C3 Glomerulopathy: Unraveling the Complement-Driven Kidney Disease

C3 glomerulopathy (C3G) is a rare but serious kidney disorder rooted in the uncontrolled activation of the alternative complement pathway. This group of diseases—encompassing dense deposit disease (DDD) and C3 glomerulonephritis (C3GN)—unfolds through a cascade of immune dysregulation that ultimately scars the kidney's filtering units. Understanding this pathogenic sequence is essential for early diagnosis and targeted therapy.

The Pathogenic Cascade: From Genetic Risk to Kidney Failure

1. Initiation: Genetic Susceptibility Meets Environmental Triggers

The journey begins with a genetic backdrop. Variants in complement regulatory genes—CFH, CFI, C3, CFB, and CFHR—create a fragile equilibrium. In individuals of African ancestry, high-risk APOL1 alleles further amplify susceptibility. But genes alone aren't enough; triggers such as infections (streptococcal, viral), autoimmune conditions, monoclonal gammopathy, or even pregnancy can tip the balance toward disease.

2. Alternative Pathway Dysregulation: The Engine of Injury

At the heart of C3G lies the C3 convertase (C3bBb), an enzyme complex that cleaves C3 into active fragments. Normally, factor H and factor I keep this convertase in check, while properdin stabilizes it. In C3G, this regulation fails—either because of deficient inhibitors, gain-of-function mutations in C3 or factor B, or autoantibodies like C3 nephritic factor. The result: runaway C3 cleavage, generating C3b, iC3b, and C3dg fragments that deposit along the glomerular basement membrane (GBM) and in the mesangium.

3. Leukocyte Recruitment: Inflammation Takes Hold

Complement activation doesn't just leave deposits—it sounds the alarm. The anaphylatoxins C3a and C5a (generated when the terminal pathway engages) act as potent chemoattractants, pulling neutrophils and macrophages into the glomerulus. These infiltrating cells unleash reactive oxygen species, proteases, and pro-inflammatory cytokines, creating a self-amplifying loop of inflammation.

4. Glomerular Structural Injury: Architecture Under Siege

Persistent inflammation remodels the glomerulus. The mesangium expands and becomes hypercellular. The GBM thickens and develops double contours—the classic "tram-tracking" seen on electron microscopy. Endothelial cells activate, and capillary walls undergo maladaptive remodeling, compromising filtration.

5. Podocyte Injury: The Final Common Pathway to Proteinuria

Podocytes, the specialized epithelial cells that wrap around capillaries, bear the brunt of terminal complement attack. The membrane attack complex (C5b-9) forms on their surface, causing sublytic injury that disrupts the cytoskeleton and leads to foot process effacement. Detached podocytes leave behind areas of segmental sclerosis, and proteinuria ensues—a hallmark of progressive disease.

6. Progression to CKD and ESRD: The Long-Term Outlook

Unchecked complement activation drives chronic inflammation, fibrosis, and tubular atrophy. Approximately 50% of patients reach end-stage renal disease (ESRD) within 10–20 years, with DDD typically progressing faster than C3GN. Post-transplant recurrence is alarmingly common (60–80%) unless complement inhibition is maintained.

Therapeutic Implications: Targeting the Complement Cascade

The complement-centric pathogenesis of C3G has spurred a new era of precision therapy:

• Complement inhibitors: Anti-C5 agents (eculizumab, ravulizumab), C3 inhibitor (pegcetacoplan), and factor B inhibitor (iptacopan) show promising trial data.
• Plasma therapy: Plasma exchange or infusion can replace deficient factor H in select genetic forms.
• Supportive care: ACE inhibitors/ARBs, SGLT2 inhibitors, blood pressure control, and lipid management remain foundational.

Genetic and functional complement profiling now guides targeted therapy selection. Early intervention—before irreversible nephron loss—offers the best chance to preserve kidney function.